Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial

Studies have suggested that evening dosing with antihypertensive therapy might have better outcomes than morning dosing. The Treatment in Morning versus Evening (TIME) study aimed to investigate whether evening dosing of usual antihypertensive medication improves major cardiovascular outcomes compar...

Full description

Saved in:

Bibliographic Details
Published in	The Lancet (British edition) Vol. 400; no. 10361; pp. 1417 - 1425
Main Authors	Mackenzie, Isla S, Rogers, Amy, Poulter, Neil R, Williams, Bryan, Brown, Morris J, Webb, David J, Ford, Ian, Rorie, David A, Guthrie, Greg, Grieve, J W Kerr, Pigazzani, Filippo, Rothwell, Peter M, Young, Robin, McConnachie, Alex, Struthers, Allan D, Lang, Chim C, MacDonald, Thomas M
Format	Journal Article
Language	English
Published	England Elsevier Ltd 22.10.2022 Elsevier Limited Elsevier
Subjects	Adolescent Adult Adults Aged Antihypertensive Agents - therapeutic use Antihypertensives Blood pressure Cardiovascular diseases Cerebral infarction Clinical trials Diuretics Dosage Female Health services Heart attacks Humans Hypertension Hypertension - chemically induced Ischemia Male Morning Myocardial infarction Myocardial Infarction - drug therapy Patient compliance Patients Prospective Studies Questionnaires Safety State Medicine Stroke Time and Motion Studies Treatment Outcome United Kingdom - epidemiology United Kingdom United Kingdom > UK Scotland
Online Access	Get full text
ISSN	0140-6736 1474-547X 1474-547X
DOI	10.1016/S0140-6736(22)01786-X

Cover

Abstract	Studies have suggested that evening dosing with antihypertensive therapy might have better outcomes than morning dosing. The Treatment in Morning versus Evening (TIME) study aimed to investigate whether evening dosing of usual antihypertensive medication improves major cardiovascular outcomes compared with morning dosing in patients with hypertension. The TIME study is a prospective, pragmatic, decentralised, parallel-group study in the UK, that recruited adults (aged ≥18 years) with hypertension and taking at least one antihypertensive medication. Eligible participants were randomly assigned (1:1), without restriction, stratification, or minimisation, to take all of their usual antihypertensive medications in either the morning (0600–1000 h) or in the evening (2000–0000 h). Participants were followed up for the composite primary endpoint of vascular death or hospitalisation for non-fatal myocardial infarction or non-fatal stroke. Endpoints were identified by participant report or record linkage to National Health Service datasets and were adjudicated by a committee masked to treatment allocation. The primary endpoint was assessed as the time to first occurrence of an event in the intention-to-treat population (ie, all participants randomly assigned to a treatment group). Safety was assessed in all participants who submitted at least one follow-up questionnaire. The study is registered with EudraCT (2011-001968-21) and ISRCTN (18157641), and is now complete. Between Dec 17, 2011, and June 5, 2018, 24 610 individuals were screened and 21 104 were randomly assigned to evening (n=10 503) or morning (n=10 601) dosing groups. Mean age at study entry was 65·1 years (SD 9·3); 12 136 (57·5%) participants were men; 8968 (42·5%) were women; 19 101 (90·5%) were White; 98 (0·5%) were Black, African, Caribbean, or Black British (ethnicity was not reported by 1637 [7·8%] participants); and 2725 (13·0%) had a previous cardiovascular disease. By the end of study follow-up (March 31, 2021), median follow-up was 5·2 years (IQR 4·9–5·7), and 529 (5·0%) of 10 503 participants assigned to evening treatment and 318 (3·0%) of 10 601 assigned to morning treatment had withdrawn from all follow-up. A primary endpoint event occurred in 362 (3·4%) participants assigned to evening treatment (0·69 events [95% CI 0·62–0·76] per 100 patient-years) and 390 (3·7%) assigned to morning treatment (0·72 events [95% CI 0·65–0·79] per 100 patient-years; unadjusted hazard ratio 0·95 [95% CI 0·83–1·10]; p=0·53). No safety concerns were identified. Evening dosing of usual antihypertensive medication was not different from morning dosing in terms of major cardiovascular outcomes. Patients can be advised that they can take their regular antihypertensive medications at a convenient time that minimises any undesirable effects. British Heart Foundation.
AbstractList	Studies have suggested that evening dosing with antihypertensive therapy might have better outcomes than morning dosing. The Treatment in Morning versus Evening (TIME) study aimed to investigate whether evening dosing of usual antihypertensive medication improves major cardiovascular outcomes compared with morning dosing in patients with hypertension. The TIME study is a prospective, pragmatic, decentralised, parallel-group study in the UK, that recruited adults (aged ≥18 years) with hypertension and taking at least one antihypertensive medication. Eligible participants were randomly assigned (1:1), without restriction, stratification, or minimisation, to take all of their usual antihypertensive medications in either the morning (0600-1000 h) or in the evening (2000-0000 h). Participants were followed up for the composite primary endpoint of vascular death or hospitalisation for non-fatal myocardial infarction or non-fatal stroke. Endpoints were identified by participant report or record linkage to National Health Service datasets and were adjudicated by a committee masked to treatment allocation. The primary endpoint was assessed as the time to first occurrence of an event in the intention-to-treat population (ie, all participants randomly assigned to a treatment group). Safety was assessed in all participants who submitted at least one follow-up questionnaire. The study is registered with EudraCT (2011-001968-21) and ISRCTN (18157641), and is now complete. Between Dec 17, 2011, and June 5, 2018, 24 610 individuals were screened and 21 104 were randomly assigned to evening (n=10 503) or morning (n=10 601) dosing groups. Mean age at study entry was 65·1 years (SD 9·3); 12 136 (57·5%) participants were men; 8968 (42·5%) were women; 19 101 (90·5%) were White; 98 (0·5%) were Black, African, Caribbean, or Black British (ethnicity was not reported by 1637 [7·8%] participants); and 2725 (13·0%) had a previous cardiovascular disease. By the end of study follow-up (March 31, 2021), median follow-up was 5·2 years (IQR 4·9-5·7), and 529 (5·0%) of 10 503 participants assigned to evening treatment and 318 (3·0%) of 10 601 assigned to morning treatment had withdrawn from all follow-up. A primary endpoint event occurred in 362 (3·4%) participants assigned to evening treatment (0·69 events [95% CI 0·62-0·76] per 100 patient-years) and 390 (3·7%) assigned to morning treatment (0·72 events [95% CI 0·65-0·79] per 100 patient-years; unadjusted hazard ratio 0·95 [95% CI 0·83-1·10]; p=0·53). No safety concerns were identified. Evening dosing of usual antihypertensive medication was not different from morning dosing in terms of major cardiovascular outcomes. Patients can be advised that they can take their regular antihypertensive medications at a convenient time that minimises any undesirable effects. British Heart Foundation. Summary Background Studies have suggested that evening dosing with antihypertensive therapy might have better outcomes than morning dosing. The Treatment in Morning versus Evening (TIME) study aimed to investigate whether evening dosing of usual antihypertensive medication improves major cardiovascular outcomes compared with morning dosing in patients with hypertension. Methods The TIME study is a prospective, pragmatic, decentralised, parallel-group study in the UK, that recruited adults (aged ≥18 years) with hypertension and taking at least one antihypertensive medication. Eligible participants were randomly assigned (1:1), without restriction, stratification, or minimisation, to take all of their usual antihypertensive medications in either the morning (0600–1000 h) or in the evening (2000–0000 h). Participants were followed up for the composite primary endpoint of vascular death or hospitalisation for non-fatal myocardial infarction or non-fatal stroke. Endpoints were identified by participant report or record linkage to National Health Service datasets and were adjudicated by a committee masked to treatment allocation. The primary endpoint was assessed as the time to first occurrence of an event in the intention-to-treat population (ie, all participants randomly assigned to a treatment group). Safety was assessed in all participants who submitted at least one follow-up questionnaire. The study is registered with EudraCT (2011-001968-21) and ISRCTN (18157641), and is now complete. Findings Between Dec 17, 2011, and June 5, 2018, 24 610 individuals were screened and 21 104 were randomly assigned to evening (n=10 503) or morning (n=10 601) dosing groups. Mean age at study entry was 65·1 years (SD 9·3); 12 136 (57·5%) participants were men; 8968 (42·5%) were women; 19 101 (90·5%) were White; 98 (0·5%) were Black, African, Caribbean, or Black British (ethnicity was not reported by 1637 [7·8%] participants); and 2725 (13·0%) had a previous cardiovascular disease. By the end of study follow-up (March 31, 2021), median follow-up was 5·2 years (IQR 4·9–5·7), and 529 (5·0%) of 10 503 participants assigned to evening treatment and 318 (3·0%) of 10 601 assigned to morning treatment had withdrawn from all follow-up. A primary endpoint event occurred in 362 (3·4%) participants assigned to evening treatment (0·69 events [95% CI 0·62–0·76] per 100 patient-years) and 390 (3·7%) assigned to morning treatment (0·72 events [95% CI 0·65–0·79] per 100 patient-years; unadjusted hazard ratio 0·95 [95% CI 0·83–1·10]; p=0·53). No safety concerns were identified. Interpretation Evening dosing of usual antihypertensive medication was not different from morning dosing in terms of major cardiovascular outcomes. Patients can be advised that they can take their regular antihypertensive medications at a convenient time that minimises any undesirable effects. Funding British Heart Foundation. Studies have suggested that evening dosing with antihypertensive therapy might have better outcomes than morning dosing. The Treatment in Morning versus Evening (TIME) study aimed to investigate whether evening dosing of usual antihypertensive medication improves major cardiovascular outcomes compared with morning dosing in patients with hypertension.BACKGROUNDStudies have suggested that evening dosing with antihypertensive therapy might have better outcomes than morning dosing. The Treatment in Morning versus Evening (TIME) study aimed to investigate whether evening dosing of usual antihypertensive medication improves major cardiovascular outcomes compared with morning dosing in patients with hypertension.The TIME study is a prospective, pragmatic, decentralised, parallel-group study in the UK, that recruited adults (aged ≥18 years) with hypertension and taking at least one antihypertensive medication. Eligible participants were randomly assigned (1:1), without restriction, stratification, or minimisation, to take all of their usual antihypertensive medications in either the morning (0600-1000 h) or in the evening (2000-0000 h). Participants were followed up for the composite primary endpoint of vascular death or hospitalisation for non-fatal myocardial infarction or non-fatal stroke. Endpoints were identified by participant report or record linkage to National Health Service datasets and were adjudicated by a committee masked to treatment allocation. The primary endpoint was assessed as the time to first occurrence of an event in the intention-to-treat population (ie, all participants randomly assigned to a treatment group). Safety was assessed in all participants who submitted at least one follow-up questionnaire. The study is registered with EudraCT (2011-001968-21) and ISRCTN (18157641), and is now complete.METHODSThe TIME study is a prospective, pragmatic, decentralised, parallel-group study in the UK, that recruited adults (aged ≥18 years) with hypertension and taking at least one antihypertensive medication. Eligible participants were randomly assigned (1:1), without restriction, stratification, or minimisation, to take all of their usual antihypertensive medications in either the morning (0600-1000 h) or in the evening (2000-0000 h). Participants were followed up for the composite primary endpoint of vascular death or hospitalisation for non-fatal myocardial infarction or non-fatal stroke. Endpoints were identified by participant report or record linkage to National Health Service datasets and were adjudicated by a committee masked to treatment allocation. The primary endpoint was assessed as the time to first occurrence of an event in the intention-to-treat population (ie, all participants randomly assigned to a treatment group). Safety was assessed in all participants who submitted at least one follow-up questionnaire. The study is registered with EudraCT (2011-001968-21) and ISRCTN (18157641), and is now complete.Between Dec 17, 2011, and June 5, 2018, 24 610 individuals were screened and 21 104 were randomly assigned to evening (n=10 503) or morning (n=10 601) dosing groups. Mean age at study entry was 65·1 years (SD 9·3); 12 136 (57·5%) participants were men; 8968 (42·5%) were women; 19 101 (90·5%) were White; 98 (0·5%) were Black, African, Caribbean, or Black British (ethnicity was not reported by 1637 [7·8%] participants); and 2725 (13·0%) had a previous cardiovascular disease. By the end of study follow-up (March 31, 2021), median follow-up was 5·2 years (IQR 4·9-5·7), and 529 (5·0%) of 10 503 participants assigned to evening treatment and 318 (3·0%) of 10 601 assigned to morning treatment had withdrawn from all follow-up. A primary endpoint event occurred in 362 (3·4%) participants assigned to evening treatment (0·69 events [95% CI 0·62-0·76] per 100 patient-years) and 390 (3·7%) assigned to morning treatment (0·72 events [95% CI 0·65-0·79] per 100 patient-years; unadjusted hazard ratio 0·95 [95% CI 0·83-1·10]; p=0·53). No safety concerns were identified.FINDINGSBetween Dec 17, 2011, and June 5, 2018, 24 610 individuals were screened and 21 104 were randomly assigned to evening (n=10 503) or morning (n=10 601) dosing groups. Mean age at study entry was 65·1 years (SD 9·3); 12 136 (57·5%) participants were men; 8968 (42·5%) were women; 19 101 (90·5%) were White; 98 (0·5%) were Black, African, Caribbean, or Black British (ethnicity was not reported by 1637 [7·8%] participants); and 2725 (13·0%) had a previous cardiovascular disease. By the end of study follow-up (March 31, 2021), median follow-up was 5·2 years (IQR 4·9-5·7), and 529 (5·0%) of 10 503 participants assigned to evening treatment and 318 (3·0%) of 10 601 assigned to morning treatment had withdrawn from all follow-up. A primary endpoint event occurred in 362 (3·4%) participants assigned to evening treatment (0·69 events [95% CI 0·62-0·76] per 100 patient-years) and 390 (3·7%) assigned to morning treatment (0·72 events [95% CI 0·65-0·79] per 100 patient-years; unadjusted hazard ratio 0·95 [95% CI 0·83-1·10]; p=0·53). No safety concerns were identified.Evening dosing of usual antihypertensive medication was not different from morning dosing in terms of major cardiovascular outcomes. Patients can be advised that they can take their regular antihypertensive medications at a convenient time that minimises any undesirable effects.INTERPRETATIONEvening dosing of usual antihypertensive medication was not different from morning dosing in terms of major cardiovascular outcomes. Patients can be advised that they can take their regular antihypertensive medications at a convenient time that minimises any undesirable effects.British Heart Foundation.FUNDINGBritish Heart Foundation.
Author	Williams, Bryan Pigazzani, Filippo MacDonald, Thomas M Rogers, Amy Rothwell, Peter M Guthrie, Greg McConnachie, Alex Webb, David J Poulter, Neil R Rorie, David A Grieve, J W Kerr Mackenzie, Isla S Ford, Ian Lang, Chim C Brown, Morris J Young, Robin Struthers, Allan D
Author_xml	– sequence: 1 givenname: Isla S surname: Mackenzie fullname: Mackenzie, Isla S organization: MEMO Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK – sequence: 2 givenname: Amy surname: Rogers fullname: Rogers, Amy organization: MEMO Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK – sequence: 3 givenname: Neil R surname: Poulter fullname: Poulter, Neil R organization: School of Public Health, Imperial College London, London, UK – sequence: 4 givenname: Bryan surname: Williams fullname: Williams, Bryan organization: NIHR University College London Hospitals Biomedical Research Centre and University College London, London, UK – sequence: 5 givenname: Morris J surname: Brown fullname: Brown, Morris J organization: Queen Mary University of London, London, UK – sequence: 6 givenname: David J surname: Webb fullname: Webb, David J organization: British Heart Foundation/University Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK – sequence: 7 givenname: Ian surname: Ford fullname: Ford, Ian organization: The Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK – sequence: 8 givenname: David A surname: Rorie fullname: Rorie, David A organization: MEMO Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK – sequence: 9 givenname: Greg surname: Guthrie fullname: Guthrie, Greg organization: MEMO Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK – sequence: 10 givenname: J W Kerr surname: Grieve fullname: Grieve, J W Kerr organization: Department of Neurology, Aberdeen Royal Infirmary, Aberdeen, UK – sequence: 11 givenname: Filippo surname: Pigazzani fullname: Pigazzani, Filippo organization: MEMO Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK – sequence: 12 givenname: Peter M surname: Rothwell fullname: Rothwell, Peter M organization: Wolfson Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK – sequence: 13 givenname: Robin surname: Young fullname: Young, Robin organization: The Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK – sequence: 14 givenname: Alex surname: McConnachie fullname: McConnachie, Alex organization: The Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK – sequence: 15 givenname: Allan D surname: Struthers fullname: Struthers, Allan D organization: Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK – sequence: 16 givenname: Chim C surname: Lang fullname: Lang, Chim C organization: Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK – sequence: 17 givenname: Thomas M surname: MacDonald fullname: MacDonald, Thomas M email: t.m.macdonald@dundee.ac.uk organization: MEMO Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/36240838$$D View this record in MEDLINE/PubMed
BookMark	eNqNks1uEzEUhUeoiKaFRwBZYpNKGbA9vwHRCkUFKopY0ErZWR77TuPi2IPtGZS35JFwkjZANmVl2f7Ose-95yg5MNZAkjwn-BXBpHz9DZMcp2WVlWNKTzCp6jKdP0pGJK_ytMir-UEy2iGHyZH3txjjvMTFk-QwK2mO66weJb9m3EllB-5Fr7lDtg_CLsEjZRCXvQ4e_VRhgRarDlwA45U12xMYwChzgwZwvvdoad1mK61fL7ZFve-5RtwE9Uc8bJ3DAtD1ZzS-uvhyjnzo5erkDeKoc9Z3IELEJshxI-1SeZATZDswqeYN6AlqtDISZApGdlaZgEQ8UCI-FZzi-mnyuOXaw7O79Ti5_nB-NfuUXn79eDF7f5mKIp-GtJCAYxuLkvMcSwmkpgQXjcAkI3WDy6aoRWwcbWXbZAB1PZWYtARXXJS1AJIdJ6db365vliAFmOC4Zp1TS-5WzHLF_r0xasFu7MCmZUZoNo0G4zsDZ3_04AOLxQrQmhuwvWe0ogXFBNdVRF_uobe2dyaWt6bKKc5onkfqxd8_2n3lftgRKLaAiH32DtodQjBbh4ptQsXWiWGUsk2o2Dzq3u7phAo8xCTEwpR-UH22VUOcxqDAMS8UGAFSuThrJq160OHdnsP9yL_D6j_0vwELX_88
CitedBy_id	crossref_primary_10_1080_07420528_2023_2253288 crossref_primary_10_1136_dtb_2023_000031 crossref_primary_10_1177_17151635231176267 crossref_primary_10_1038_s41591_024_03273_3 crossref_primary_10_5937_Galmed2409041I crossref_primary_10_15212_CVIA_2023_0054 crossref_primary_10_1016_j_amjmed_2023_06_019 crossref_primary_10_1007_s11906_023_01277_x crossref_primary_10_15829_1560_4071_2024_6117 crossref_primary_10_3389_fendo_2023_1083179 crossref_primary_10_62751_2713_0177_2024_5_1_06 crossref_primary_10_36290_vnl_2023_008 crossref_primary_10_1097_HJH_0000000000003352 crossref_primary_10_1161_CIRCRESAHA_122_321762 crossref_primary_10_1097_HJH_0000000000003353 crossref_primary_10_15829_1728_8800_2023_3539 crossref_primary_10_1186_s40885_023_00249_2 crossref_primary_10_1080_07420528_2024_2362972 crossref_primary_10_18705_1607_419X_2023_29_2_231_240 crossref_primary_10_1186_s40001_023_01158_8 crossref_primary_10_3390_medicina60091522 crossref_primary_10_1007_s12325_023_02502_4 crossref_primary_10_1007_s40266_023_01013_9 crossref_primary_10_1161_CIRCRESAHA_123_323049 crossref_primary_10_1016_j_eclinm_2024_102768 crossref_primary_10_1097_HJH_0000000000003480 crossref_primary_10_1097_HJH_0000000000003360 crossref_primary_10_1111_jebm_12548 crossref_primary_10_1038_s41440_023_01562_x crossref_primary_10_1097_HJH_0000000000003783 crossref_primary_10_22141_2224_1485_17_4_2024_372 crossref_primary_10_18231_j_jpbs_2024_016 crossref_primary_10_1038_s41440_023_01376_x crossref_primary_10_15829_1728_8800_2024_4140 crossref_primary_10_1038_s41569_022_00801_x crossref_primary_10_1161_HYPERTENSIONAHA_123_21725 crossref_primary_10_15829_1560_4071_2023_5395 crossref_primary_10_1007_s00421_023_05369_z crossref_primary_10_1016_j_med_2024_11_021 crossref_primary_10_1186_s40885_024_00265_w crossref_primary_10_1080_17512433_2024_2304015 crossref_primary_10_1097_HJH_0000000000003891 crossref_primary_10_1016_j_eprac_2025_02_015 crossref_primary_10_1093_ehjcvp_pvad017 crossref_primary_10_1097_HJH_0000000000003816 crossref_primary_10_14797_mdcvj_1175 crossref_primary_10_1161_HYPERTENSIONAHA_122_19372 crossref_primary_10_3389_fendo_2023_1110459 crossref_primary_10_1111_jch_14790 crossref_primary_10_1136_dtb_2022_000069 crossref_primary_10_17816_KMJ626252 crossref_primary_10_1016_S0140_6736_22_01900_6 crossref_primary_10_1038_s41440_024_01694_8 crossref_primary_10_1136_bmjopen_2023_074777 crossref_primary_10_1136_dtb_2023_000002 crossref_primary_10_1161_HYPERTENSIONAHA_124_23724 crossref_primary_10_1038_s41433_023_02555_3 crossref_primary_10_1007_s00112_024_02058_9 crossref_primary_10_1186_s12890_023_02757_1 crossref_primary_10_1007_s40119_023_00313_w crossref_primary_10_1136_bmjopen_2022_068188 crossref_primary_10_1080_17512433_2023_2233438 crossref_primary_10_1007_s11906_023_01274_0 crossref_primary_10_1080_07420528_2024_2414878 crossref_primary_10_3399_bjgp23X731493 crossref_primary_10_1097_HJH_0000000000003950 crossref_primary_10_1007_s00508_024_02440_3 crossref_primary_10_1080_08037051_2022_2142512 crossref_primary_10_1161_CIR_0000000000001209 crossref_primary_10_1007_s10741_024_10447_1 crossref_primary_10_1016_j_cjca_2023_06_416 crossref_primary_10_1016_j_biopha_2023_115422 crossref_primary_10_1111_joim_13678 crossref_primary_10_1097_HJH_0000000000003799 crossref_primary_10_1161_CIRCRESAHA_124_323508 crossref_primary_10_3399_bjgp23X731517 crossref_primary_10_1152_ajprenal_00247_2023 crossref_primary_10_61409_V11230700 crossref_primary_10_1093_ajh_hpae035 crossref_primary_10_1093_ajh_hpaf008 crossref_primary_10_1097_CRD_0000000000000644 crossref_primary_10_1016_j_cjca_2023_07_002 crossref_primary_10_1097_HJH_0000000000003508 crossref_primary_10_1038_s41440_023_01359_y crossref_primary_10_1093_eurjpc_zwac245 crossref_primary_10_1016_j_amjmed_2023_02_018 crossref_primary_10_1016_j_arbres_2023_03_006 crossref_primary_10_1097_HJH_0000000000003732 crossref_primary_10_4103_jrms_jrms_470_23 crossref_primary_10_1016_j_eclinm_2024_102633 crossref_primary_10_1161_CIR_0000000000001303 crossref_primary_10_1016_j_jacc_2024_02_059 crossref_primary_10_1038_s41440_022_01158_x crossref_primary_10_1016_j_bj_2025_100849 crossref_primary_10_3389_fimmu_2025_1556057 crossref_primary_10_1177_87551225231207275 crossref_primary_10_2174_1573402119666230109142156 crossref_primary_10_1111_jch_14757 crossref_primary_10_1097_HJH_0000000000003581 crossref_primary_10_1186_s13063_023_07726_x
Cites_doi	10.1093/eurheartj/ehz754 10.1161/HYPERTENSIONAHA.121.17356 10.1161/HYPERTENSIONAHA.120.16500 10.1186/1471-2318-13-50 10.1161/HYPERTENSIONAHA.115.06981 10.1136/bmjopen-2016-013351 10.1038/jhh.2009.9 10.1161/HYPERTENSIONAHA.110.157149 10.1136/bmjopen-2018-021890 10.1097/01.hjh.0000182522.21569.c5 10.1186/1472-6947-9-3 10.1136/bmjopen-2021-059711 10.1016/S0140-6736(20)30752-2 10.1161/hy1001.092640 10.1038/s41371-020-00469-1 10.1161/HYPERTENSIONAHA.121.16501 10.1093/ajh/hpv016 10.1136/bmjopen-2015-010313 10.1097/HJH.0000000000003240 10.1136/bmj.39553.670231.25 10.1186/s13063-017-2318-4 10.3109/07420528.2010.510230 10.1038/s41371-021-00511-w 10.1016/S0140-6736(20)32234-0 10.1016/S0140-6736(21)00590-0 10.1038/s41371-021-00496-6 10.1161/HYPERTENSIONAHA.118.11101 10.1111/bcp.15205 10.1093/abm/kaaa042 10.1136/openhrt-2020-001461 10.1038/s41371-021-00621-5
ContentType	Journal Article
Copyright	2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. 2022. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2022
Copyright_xml	– notice: 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license – notice: Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. – notice: 2022. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2022
CorporateAuthor	TIME Study Group
CorporateAuthor_xml	– name: TIME Study Group
DBID	6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7X8 5PM
DOI	10.1016/S0140-6736(22)01786-X
DatabaseName	ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Proquest Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central ProQuest One Sustainability ProQuest Central UK/Ireland British Nursing Database (Proquest) British Nursing Index ProQuest Central Essentials Biological Science Collection eLibrary - Proquest. Click here to access. ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Psychology Database ProQuest Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE ProQuest One Psychology MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1474-547X
EndPage	1425
ExternalDocumentID	PMC9631239 36240838 10_1016_S0140_6736_22_01786_X S014067362201786X
Genre	Randomized Controlled Trial Journal Article
GeographicLocations	United Kingdom United Kingdom--UK Scotland
GeographicLocations_xml	– name: United Kingdom – name: United Kingdom--UK – name: Scotland
GrantInformation	British Heart Foundation.
GrantInformation_xml	– fundername: Medical Research Council grantid: MC_PC_17228 – fundername: Medical Research Council grantid: MC_QA137853
GroupedDBID	--- --K --M .1- .55 .CO .FO 0R~ 123 1B1 1P~ 1RT 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUWG ACGFS ACGOD ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGCQF AGHFR AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EFKBS EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M41 M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ PUEGO ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UV1 WOW X7M XAX XDU YYM Z5R ZMT 6I. AACTN AAFTH AFCTW ALIPV .GJ 04C 3EH 3O- 41~ 8WZ A6W AAEJM AAKAS AAQQT AAQXK AAYOK AAYXX ABDBF ABWVN ACRPL ACUHS ADMUD ADNMO ADXHL ADZCM AFFNX AGQPQ AGRNS AHHHB AHQJS AJJEV AKVCP ARTTT ASPBG AVWKF AZFZN CITATION D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EJD EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H MVM OVD Q~Q R2- RIG SV3 TEORI TH9 UHU UQL WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7TK 7U7 7U9 7XB 88A 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 ACLOT ~HD 5PM
ID	FETCH-LOGICAL-c549t-5de001656aa40dde182105bc01318b06b58c7362fdfb3ee889d01f107ac68ce13
IEDL.DBID	8C1
ISSN	0140-6736 1474-547X
IngestDate	Thu Aug 21 18:39:44 EDT 2025 Sun Sep 28 11:42:27 EDT 2025 Fri Aug 22 09:40:35 EDT 2025 Mon Jul 21 06:08:03 EDT 2025 Thu Apr 24 22:51:19 EDT 2025 Tue Jul 01 04:23:56 EDT 2025 Sun Apr 06 06:54:40 EDT 2025 Tue Aug 26 16:42:36 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	10361
Language	English
License	This is an open access article under the CC BY license. Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c549t-5de001656aa40dde182105bc01318b06b58c7362fdfb3ee889d01f107ac68ce13
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 Other members of the TIME Study Group and contributors are listed in the appendix (p 17)
OpenAccessLink	https://pubmed.ncbi.nlm.nih.gov/PMC9631239
PMID	36240838
PQID	2726903244
PQPubID	40246
PageCount	9
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_9631239 proquest_miscellaneous_2725201087 proquest_journals_2726903244 pubmed_primary_36240838 crossref_primary_10_1016_S0140_6736_22_01786_X crossref_citationtrail_10_1016_S0140_6736_22_01786_X elsevier_sciencedirect_doi_10_1016_S0140_6736_22_01786_X elsevier_clinicalkey_doi_10_1016_S0140_6736_22_01786_X
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2022-10-22
PublicationDateYYYYMMDD	2022-10-22
PublicationDate_xml	– month: 10 year: 2022 text: 2022-10-22 day: 22
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England – name: London
PublicationTitle	The Lancet (British edition)
PublicationTitleAlternate	Lancet
PublicationYear	2022
Publisher	Elsevier Ltd Elsevier Limited Elsevier
Publisher_xml	– name: Elsevier Ltd – name: Elsevier Limited – name: Elsevier
References	Bowe, Grünig, Schubert (bib13) 2015; 28 Vickneson, Rogers, Anbarasan, Rorie, MacDonald, Mackenzie (bib26) 2021 McKinstry, Sullivan, Vasishta (bib20) 2017; 7 (bib1) 2020; 396 Hermida, Mojón, Smolensky, Fernández (bib17) 2021; 78 Kario (bib5) 2010; 56 Rahimi, Bidel, Nazarzadeh (bib2) 2021; 397 Vrijens, Vincze, Kristanto, Urquhart, Burnier (bib16) 2008; 336 MacDonald, Hawkey, Ford (bib28) 2017; 38 Hermida, Calvo, Ayala (bib6) 2005; 23 Anbarasan, Rogers, Rorie (bib24) 2022; 36 Ho, Chowdhury, Doust, Nelson, Reid (bib30) 2021; 35 Rorie, Flynn, Mackenzie, MacDonald, Rogers (bib19) 2017; 18 Rogers, De Paoli, Subbarayan (bib22) 2022; 88 Kario, Pickering, Matsuo, Hoshide, Schwartz, Shimada (bib14) 2001; 38 Hermida, Crespo, Domínguez-Sardiña (bib10) 2020; 41 Stergiou, Brunström, MacDonald (bib8) 2022; 40 Tapela, Collister, Clifton, Turnbull, Rahimi, Hunter (bib31) 2021; 8 Turgeon, Althouse, Cohen (bib11) 2021; 78 Poulter, Savopoulos, Anjum (bib7) 2018; 72 Fagard, Thijs, Staessen, Clement, De Buyzere, De Bacquer (bib3) 2009; 23 Brunström, Kjeldsen, Kreutz (bib18) 2021; 78 Hermida, Ayala, Mojón, Fernández (bib9) 2010; 27 Salles, Reboldi, Fagard (bib4) 2016; 67 Garrison, Kolber, Allan (bib33) 2022; 12 Phillips, Burns, Leventhal (bib15) 2021; 55 Mackenzie, Ford, Nuki (bib29) 2020; 396 Roberts (bib32) Oct 23, 2019 Lyons, Jones, John (bib23) 2009; 9 Rogers, Morrison, Rorie, Mackenzie, MacDonald (bib27) 2018; 8 Anbarasan, Rogers, Rorie, Grieve, MacDonald, Mackenzie (bib25) 2022; 36 Rorie, Rogers, Mackenzie (bib21) 2016; 6 Klein, Nagel, Kleiner (bib12) 2013; 13 Hermida (10.1016/S0140-6736(22)01786-X_bib9) 2010; 27 MacDonald (10.1016/S0140-6736(22)01786-X_bib28) 2017; 38 Poulter (10.1016/S0140-6736(22)01786-X_bib7) 2018; 72 Ho (10.1016/S0140-6736(22)01786-X_bib30) 2021; 35 Turgeon (10.1016/S0140-6736(22)01786-X_bib11) 2021; 78 Brunström (10.1016/S0140-6736(22)01786-X_bib18) 2021; 78 Hermida (10.1016/S0140-6736(22)01786-X_bib17) 2021; 78 Rorie (10.1016/S0140-6736(22)01786-X_bib19) 2017; 18 Kario (10.1016/S0140-6736(22)01786-X_bib14) 2001; 38 Fagard (10.1016/S0140-6736(22)01786-X_bib3) 2009; 23 Stergiou (10.1016/S0140-6736(22)01786-X_bib8) 2022; 40 Anbarasan (10.1016/S0140-6736(22)01786-X_bib24) 2022; 36 Salles (10.1016/S0140-6736(22)01786-X_bib4) 2016; 67 Rahimi (10.1016/S0140-6736(22)01786-X_bib2) 2021; 397 Bowe (10.1016/S0140-6736(22)01786-X_bib13) 2015; 28 Rogers (10.1016/S0140-6736(22)01786-X_bib22) 2022; 88 Roberts (10.1016/S0140-6736(22)01786-X_bib32) (10.1016/S0140-6736(22)01786-X_bib1) 2020; 396 Rogers (10.1016/S0140-6736(22)01786-X_bib27) 2018; 8 Hermida (10.1016/S0140-6736(22)01786-X_bib6) 2005; 23 Kario (10.1016/S0140-6736(22)01786-X_bib5) 2010; 56 Vickneson (10.1016/S0140-6736(22)01786-X_bib26) 2021 Hermida (10.1016/S0140-6736(22)01786-X_bib10) 2020; 41 Rorie (10.1016/S0140-6736(22)01786-X_bib21) 2016; 6 Lyons (10.1016/S0140-6736(22)01786-X_bib23) 2009; 9 Mackenzie (10.1016/S0140-6736(22)01786-X_bib29) 2020; 396 Tapela (10.1016/S0140-6736(22)01786-X_bib31) 2021; 8 Vrijens (10.1016/S0140-6736(22)01786-X_bib16) 2008; 336 Phillips (10.1016/S0140-6736(22)01786-X_bib15) 2021; 55 Anbarasan (10.1016/S0140-6736(22)01786-X_bib25) 2022; 36 Garrison (10.1016/S0140-6736(22)01786-X_bib33) 2022; 12 Klein (10.1016/S0140-6736(22)01786-X_bib12) 2013; 13 McKinstry (10.1016/S0140-6736(22)01786-X_bib20) 2017; 7 36240839 - Lancet. 2022 Oct 22;400(10361):1383-1385. doi: 10.1016/S0140-6736(22)01900-6. 36319686 - Nat Rev Cardiol. 2023 Jan;20(1):3. doi: 10.1038/s41569-022-00801-x. 36745893 - Ann Intern Med. 2023 Feb;176(2):JC16. doi: 10.7326/J22-0116. 36894302 - Drug Ther Bull. 2023 Apr;61(4):50. doi: 10.1136/dtb.2022.000069.
References_xml	– volume: 8 year: 2018 ident: bib27 article-title: Protocol for assessment of sleep quality and duration in the Treatment In Morning versus Evening (TIME) study: a randomised controlled trial using online patient-reported outcome measures publication-title: BMJ Open – year: Oct 23, 2019 ident: bib32 article-title: Blood pressure pills ‘work better at bedtime’. BBC News – year: 2021 ident: bib26 article-title: Factors influencing participation and long-term commitment to self-monitoring of blood pressure in a large remote clinical trial: the treatment in morning versus evening (TIME) study publication-title: J Hum Hypertens – volume: 13 start-page: 50 year: 2013 ident: bib12 article-title: Blood pressure and falls in community-dwelling people aged 60 years and older in the VHM&PP cohort publication-title: BMC Geriatr – volume: 6 year: 2016 ident: bib21 article-title: Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study publication-title: BMJ Open – volume: 78 start-page: 871 year: 2021 end-page: 878 ident: bib11 article-title: Lowering nighttime blood pressure with bedtime dosing of antihypertensive medications: controversies in hypertension - con side of the argument publication-title: Hypertension – volume: 336 start-page: 1114 year: 2008 end-page: 1117 ident: bib16 article-title: Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories publication-title: BMJ – volume: 23 start-page: 645 year: 2009 end-page: 653 ident: bib3 article-title: Night-day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension publication-title: J Hum Hypertens – volume: 88 start-page: 2843 year: 2022 end-page: 2862 ident: bib22 article-title: A systematic review of methods used to conduct decentralised clinical trials publication-title: Br J Clin Pharmacol – volume: 67 start-page: 693 year: 2016 end-page: 700 ident: bib4 article-title: Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: the Ambulatory Blood Pressure Collaboration in patients with Hypertension (ABC-H) meta-analysis publication-title: Hypertension – volume: 396 start-page: 1223 year: 2020 end-page: 1249 ident: bib1 article-title: Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 publication-title: Lancet – volume: 12 year: 2022 ident: bib33 article-title: Bedtime versus morning use of antihypertensives for cardiovascular risk reduction (BedMed): protocol for a prospective, randomised, open-label, blinded end-point pragmatic trial publication-title: BMJ Open – volume: 27 start-page: 1629 year: 2010 end-page: 1651 ident: bib9 article-title: Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study publication-title: Chronobiol Int – volume: 40 start-page: 1847 year: 2022 end-page: 1858 ident: bib8 article-title: Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension publication-title: J Hypertens – volume: 9 start-page: 3 year: 2009 ident: bib23 article-title: The SAIL databank: linking multiple health and social care datasets publication-title: BMC Med Inform Decis Mak – volume: 7 year: 2017 ident: bib20 article-title: Cohort profile: the Scottish Research Register SHARE. A register of people interested in research participation linked to NHS data sets publication-title: BMJ Open – volume: 78 start-page: 555 year: 2021 end-page: 558 ident: bib18 article-title: Missing verification of source data in hypertension research: the HYGIA PROJECT in perspective publication-title: Hypertension – volume: 35 start-page: 308 year: 2021 end-page: 314 ident: bib30 article-title: The effect of taking blood pressure lowering medication at night on cardiovascular disease risk. A systematic review publication-title: J Hum Hypertens – volume: 397 start-page: 1625 year: 2021 end-page: 1636 ident: bib2 article-title: Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis publication-title: Lancet – volume: 78 start-page: 879 year: 2021 end-page: 893 ident: bib17 article-title: Lowering nighttime blood pressure with bedtime dosing of antihypertensive medications: controversies in hypertension-pro side of the argument publication-title: Hypertension – volume: 56 start-page: 765 year: 2010 end-page: 773 ident: bib5 article-title: Morning surge in blood pressure and cardiovascular risk: evidence and perspectives publication-title: Hypertension – volume: 23 start-page: 1913 year: 2005 end-page: 1922 ident: bib6 article-title: Treatment of non-dipper hypertension with bedtime administration of valsartan publication-title: J Hypertens – volume: 41 start-page: 4565 year: 2020 end-page: 4576 ident: bib10 article-title: Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial publication-title: Eur Heart J – volume: 36 start-page: 32 year: 2022 end-page: 39 ident: bib25 article-title: Home blood pressure monitors owned by participants in a large decentralised clinical trial in hypertension: the Treatment In Morning versus Evening (TIME) study publication-title: J Hum Hypertens – volume: 72 start-page: 870 year: 2018 end-page: 873 ident: bib7 article-title: Randomized crossover trial of the impact of morning or evening dosing of antihypertensive agents on 24-hour ambulatory blood pressure publication-title: Hypertension – volume: 28 start-page: 1077 year: 2015 end-page: 1082 ident: bib13 article-title: Circadian variation in arterial blood pressure and glaucomatous optic neuropathy—a systematic review and meta-analysis publication-title: Am J Hypertens – volume: 55 start-page: 280 year: 2021 end-page: 285 ident: bib15 article-title: Time-of-day differences in treatment-related habit strength and adherence publication-title: Ann Behav Med – volume: 8 year: 2021 ident: bib31 article-title: Prevalence and determinants of hypertension control among almost 100 000 treated adults in the UK publication-title: Open Heart – volume: 38 start-page: 852 year: 2001 end-page: 857 ident: bib14 article-title: Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives publication-title: Hypertension – volume: 38 start-page: 1843 year: 2017 end-page: 1850 ident: bib28 article-title: Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT) publication-title: Eur Heart J – volume: 36 start-page: 325 year: 2022 end-page: 332 ident: bib24 article-title: Factors influencing home blood pressure monitor ownership in a large clinical trial publication-title: J Hum Hypertens – volume: 396 start-page: 1745 year: 2020 end-page: 1757 ident: bib29 article-title: Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial publication-title: Lancet – volume: 18 start-page: 557 year: 2017 ident: bib19 article-title: The Treatment In Morning versus Evening (TIME) study: analysis of recruitment, follow-up and retention rates post-recruitment publication-title: Trials – volume: 41 start-page: 4565 year: 2020 ident: 10.1016/S0140-6736(22)01786-X_bib10 article-title: Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial publication-title: Eur Heart J doi: 10.1093/eurheartj/ehz754 – volume: 78 start-page: 555 year: 2021 ident: 10.1016/S0140-6736(22)01786-X_bib18 article-title: Missing verification of source data in hypertension research: the HYGIA PROJECT in perspective publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.121.17356 – volume: 78 start-page: 879 year: 2021 ident: 10.1016/S0140-6736(22)01786-X_bib17 article-title: Lowering nighttime blood pressure with bedtime dosing of antihypertensive medications: controversies in hypertension-pro side of the argument publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.120.16500 – volume: 13 start-page: 50 year: 2013 ident: 10.1016/S0140-6736(22)01786-X_bib12 article-title: Blood pressure and falls in community-dwelling people aged 60 years and older in the VHM&PP cohort publication-title: BMC Geriatr doi: 10.1186/1471-2318-13-50 – volume: 67 start-page: 693 year: 2016 ident: 10.1016/S0140-6736(22)01786-X_bib4 article-title: Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: the Ambulatory Blood Pressure Collaboration in patients with Hypertension (ABC-H) meta-analysis publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.115.06981 – volume: 7 year: 2017 ident: 10.1016/S0140-6736(22)01786-X_bib20 article-title: Cohort profile: the Scottish Research Register SHARE. A register of people interested in research participation linked to NHS data sets publication-title: BMJ Open doi: 10.1136/bmjopen-2016-013351 – volume: 23 start-page: 645 year: 2009 ident: 10.1016/S0140-6736(22)01786-X_bib3 article-title: Night-day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension publication-title: J Hum Hypertens doi: 10.1038/jhh.2009.9 – volume: 56 start-page: 765 year: 2010 ident: 10.1016/S0140-6736(22)01786-X_bib5 article-title: Morning surge in blood pressure and cardiovascular risk: evidence and perspectives publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.110.157149 – volume: 8 year: 2018 ident: 10.1016/S0140-6736(22)01786-X_bib27 article-title: Protocol for assessment of sleep quality and duration in the Treatment In Morning versus Evening (TIME) study: a randomised controlled trial using online patient-reported outcome measures publication-title: BMJ Open doi: 10.1136/bmjopen-2018-021890 – volume: 23 start-page: 1913 year: 2005 ident: 10.1016/S0140-6736(22)01786-X_bib6 article-title: Treatment of non-dipper hypertension with bedtime administration of valsartan publication-title: J Hypertens doi: 10.1097/01.hjh.0000182522.21569.c5 – volume: 9 start-page: 3 year: 2009 ident: 10.1016/S0140-6736(22)01786-X_bib23 article-title: The SAIL databank: linking multiple health and social care datasets publication-title: BMC Med Inform Decis Mak doi: 10.1186/1472-6947-9-3 – volume: 12 year: 2022 ident: 10.1016/S0140-6736(22)01786-X_bib33 article-title: Bedtime versus morning use of antihypertensives for cardiovascular risk reduction (BedMed): protocol for a prospective, randomised, open-label, blinded end-point pragmatic trial publication-title: BMJ Open doi: 10.1136/bmjopen-2021-059711 – volume: 396 start-page: 1223 year: 2020 ident: 10.1016/S0140-6736(22)01786-X_bib1 article-title: Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 publication-title: Lancet doi: 10.1016/S0140-6736(20)30752-2 – volume: 38 start-page: 852 year: 2001 ident: 10.1016/S0140-6736(22)01786-X_bib14 article-title: Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives publication-title: Hypertension doi: 10.1161/hy1001.092640 – volume: 35 start-page: 308 year: 2021 ident: 10.1016/S0140-6736(22)01786-X_bib30 article-title: The effect of taking blood pressure lowering medication at night on cardiovascular disease risk. A systematic review publication-title: J Hum Hypertens doi: 10.1038/s41371-020-00469-1 – volume: 78 start-page: 871 year: 2021 ident: 10.1016/S0140-6736(22)01786-X_bib11 article-title: Lowering nighttime blood pressure with bedtime dosing of antihypertensive medications: controversies in hypertension - con side of the argument publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.121.16501 – volume: 28 start-page: 1077 year: 2015 ident: 10.1016/S0140-6736(22)01786-X_bib13 article-title: Circadian variation in arterial blood pressure and glaucomatous optic neuropathy—a systematic review and meta-analysis publication-title: Am J Hypertens doi: 10.1093/ajh/hpv016 – volume: 38 start-page: 1843 year: 2017 ident: 10.1016/S0140-6736(22)01786-X_bib28 article-title: Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT) publication-title: Eur Heart J – volume: 6 year: 2016 ident: 10.1016/S0140-6736(22)01786-X_bib21 article-title: Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study publication-title: BMJ Open doi: 10.1136/bmjopen-2015-010313 – volume: 40 start-page: 1847 year: 2022 ident: 10.1016/S0140-6736(22)01786-X_bib8 article-title: Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension publication-title: J Hypertens doi: 10.1097/HJH.0000000000003240 – volume: 336 start-page: 1114 year: 2008 ident: 10.1016/S0140-6736(22)01786-X_bib16 article-title: Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories publication-title: BMJ doi: 10.1136/bmj.39553.670231.25 – volume: 18 start-page: 557 year: 2017 ident: 10.1016/S0140-6736(22)01786-X_bib19 article-title: The Treatment In Morning versus Evening (TIME) study: analysis of recruitment, follow-up and retention rates post-recruitment publication-title: Trials doi: 10.1186/s13063-017-2318-4 – volume: 27 start-page: 1629 year: 2010 ident: 10.1016/S0140-6736(22)01786-X_bib9 article-title: Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study publication-title: Chronobiol Int doi: 10.3109/07420528.2010.510230 – volume: 36 start-page: 325 year: 2022 ident: 10.1016/S0140-6736(22)01786-X_bib24 article-title: Factors influencing home blood pressure monitor ownership in a large clinical trial publication-title: J Hum Hypertens doi: 10.1038/s41371-021-00511-w – volume: 396 start-page: 1745 year: 2020 ident: 10.1016/S0140-6736(22)01786-X_bib29 article-title: Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial publication-title: Lancet doi: 10.1016/S0140-6736(20)32234-0 – volume: 397 start-page: 1625 year: 2021 ident: 10.1016/S0140-6736(22)01786-X_bib2 article-title: Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis publication-title: Lancet doi: 10.1016/S0140-6736(21)00590-0 – volume: 36 start-page: 32 year: 2022 ident: 10.1016/S0140-6736(22)01786-X_bib25 article-title: Home blood pressure monitors owned by participants in a large decentralised clinical trial in hypertension: the Treatment In Morning versus Evening (TIME) study publication-title: J Hum Hypertens doi: 10.1038/s41371-021-00496-6 – volume: 72 start-page: 870 year: 2018 ident: 10.1016/S0140-6736(22)01786-X_bib7 article-title: Randomized crossover trial of the impact of morning or evening dosing of antihypertensive agents on 24-hour ambulatory blood pressure publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.118.11101 – volume: 88 start-page: 2843 year: 2022 ident: 10.1016/S0140-6736(22)01786-X_bib22 article-title: A systematic review of methods used to conduct decentralised clinical trials publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.15205 – volume: 55 start-page: 280 year: 2021 ident: 10.1016/S0140-6736(22)01786-X_bib15 article-title: Time-of-day differences in treatment-related habit strength and adherence publication-title: Ann Behav Med doi: 10.1093/abm/kaaa042 – volume: 8 year: 2021 ident: 10.1016/S0140-6736(22)01786-X_bib31 article-title: Prevalence and determinants of hypertension control among almost 100 000 treated adults in the UK publication-title: Open Heart doi: 10.1136/openhrt-2020-001461 – year: 2021 ident: 10.1016/S0140-6736(22)01786-X_bib26 article-title: Factors influencing participation and long-term commitment to self-monitoring of blood pressure in a large remote clinical trial: the treatment in morning versus evening (TIME) study publication-title: J Hum Hypertens doi: 10.1038/s41371-021-00621-5 – ident: 10.1016/S0140-6736(22)01786-X_bib32 – reference: 36745893 - Ann Intern Med. 2023 Feb;176(2):JC16. doi: 10.7326/J22-0116. – reference: 36319686 - Nat Rev Cardiol. 2023 Jan;20(1):3. doi: 10.1038/s41569-022-00801-x. – reference: 36240839 - Lancet. 2022 Oct 22;400(10361):1383-1385. doi: 10.1016/S0140-6736(22)01900-6. – reference: 36894302 - Drug Ther Bull. 2023 Apr;61(4):50. doi: 10.1136/dtb.2022.000069.
SSID	ssj0004605
Score	2.6813352
Snippet	Studies have suggested that evening dosing with antihypertensive therapy might have better outcomes than morning dosing. The Treatment in Morning versus... Summary Background Studies have suggested that evening dosing with antihypertensive therapy might have better outcomes than morning dosing. The Treatment in...
SourceID	pubmedcentral proquest pubmed crossref elsevier
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	1417
SubjectTerms	Adolescent Adult Adults Aged Antihypertensive Agents - therapeutic use Antihypertensives Blood pressure Cardiovascular diseases Cerebral infarction Clinical trials Diuretics Dosage Female Health services Heart attacks Humans Hypertension Hypertension - chemically induced Ischemia Male Morning Myocardial infarction Myocardial Infarction - drug therapy Patient compliance Patients Prospective Studies Questionnaires Safety State Medicine Stroke Time and Motion Studies Treatment Outcome United Kingdom - epidemiology
Title	Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S014067362201786X https://dx.doi.org/10.1016/S0140-6736(22)01786-X https://www.ncbi.nlm.nih.gov/pubmed/36240838 https://www.proquest.com/docview/2726903244 https://www.proquest.com/docview/2725201087 https://pubmed.ncbi.nlm.nih.gov/PMC9631239
Volume	400
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfYJiFe0Phc2KgOiYdNqlnqJo7LC4Kq0wB1QrBKfYsS29UqlaQsCX8nfxJ3zkcpDMZrkkvr3Pm-fPc7xl6aQSqHi0Ry3DqGB6HWHOOsAdc-ocVJMVKS-p2nF_J8FnyYh_Mm4VY0ZZWtTnSK2uSacuSnIhIYyKH5D96sv3GaGkWnq80IjR22Rz2gFHyp8eCmvkhX4r7p4Dn90l08FuKEZtRLPv-bbfrT9_y9hPIXm3S2z-43ziS8rbn_gN2x2UN2d9oclz9iP8Zb1aaQVyUu1hawzMABbxRAeVi4wmD02pWy51l9hXCd0KgBFW1UBXzNXf4ETE6pBcgXUBUV_jKyZbkh_l6_GV1KmH2E48v30wk4-NqT15AArq5t6-wDWkiTo4hZ0wca4MVRGO2qD-mK4BsNt5lZ58ushLZzE9x4kcdsdja5HJ_zZoQD1xh4ljw0lpzKUCZJ4KM4YDSDDl2qCeVHpb5MQ6WRB2JhFunQWqVGxh8sMCRNtFTaDoZP2G6WZ_aAgU1TkSZD6RstA4walQoNvjlMbORHUiYeC1rmxbrBN6cxG6v4hkI2IWLH83jusVcd2boG-LiNQLaSEbffAPVtjCboNkLVETbuTe22_A_pUSuCcaNjinizIzz2oruNrKMjnySzeeWeCaneQUUee1pLbLdK_OwBOuDKY9GWLHcPEPL49p1seeUQyFFro8czevbvv3XI7glqFkFLL8QR2y2vK_scXbgy7bGdaB713G7tsb13k4tPn38CO_lG4w
linkProvider	ProQuest
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwELZGJwFfEO8EBhwSSJtUs9RNHBdpQjA6tXStELRSv4XEdrVKJSlLA-LP8Rv4SZydl1IYjC_7muScxD7fPXe-F0KeqlbM27OIU9w6inq-lBTtrBaVrqkWx1lHcJPvPBzx3sR7O_WnW-R7lQtjwiormWgFtUql8ZHvs4ChIYfq33u5_ExN1yhzulq10IjK1grqwJYYKxM7BvrbVzThsoP-G1zvZ4wddceHPVp2GaASbaMV9ZU2uMfnUeS5-MUIuBFzxNIUohGxy2NfyADF_EzN4rbWQnSU25qh1RRJLqRutXHcS2TbMw6UBtl-3R29e39WZqYNsl_nEO1_qC_uMraHG0NwOv2bdvwT_f4exPmLVjy6Tq6VcBZeFfx3g2zp5Ca5PCwP7G-RH4cb8a6Q5iucbp3BPAFb-iMD4wmGEzSHT20wfZoUV0xlKVSrYMJG8gw-pdaDAyo1zg1IZ5BnOb4ZGWO-Jv5SjIygFiYD2B33h12wBXT3XkAE-HdVYmkTUEerFJlcqyaYFmIUt4NeNCFemAKSiupELdN5soIqdxRsg5PbZHIhy3uHNJI00fcI6DhmcdTmrpLcQ7tVCF_hyH6kAzfgPHKIVy1eKMsK66bRxyI8I5SOsdCueTh1yPOabFmUGDmPgFecEVZzgBI_RCV4HqGoCUuAVQCn_yHdqVgwLKVcFq73pEOe1Ldx6cyhU5ToNLfP-CbiQgQOuVtwbP2XOO0emgDCIcEGL9cPmNrnm3eS-YmtgY56AzFX5_6_P-sxudIbD4_D4_5o8IBcZSZ1BXEHYzuksTrN9UMElKv4UblrgXy8aEHxE1HFh6U
linkToPdf	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGJk28IL4pDDgkkDapXlM3cVykCcHWaqW0mmCV-hYS29EqlaQsDYh_kSf-JM7ORykMxstek5yT-M53v7Pvg5Dnqh3xThxyiktHUdeTkqKf1abSMdXiOOsKbvKdR2N-PHHfTr3pBvle5cKYsMpKJ1pFrVJp9shbzGfoyKH5d1txGRZxctR_tfhMTQcpc9JatdMIyzYL6sCWGyuTPIb621d057KDwRHy_gVj_d7p4TEtOw5QiX7SknpKGwzk8TB0Hfx6BN-IPyJpitKIyOGRJ6SPKj9WcdTRWoiuctoxelCh5ELqdgfHvUa2fLT66AhuvemNT95flKVpA-5X-UStD_XFXcb2cJEITqd_s5R_IuHfAzp_sZD9m-RGCW3hdSGLt8iGTm6T7VF5eH-H_Dhci32FNF_i1OsMZgnYMiAZmF1hOEPX-NwG1qdJccVUmUITCyaEJM_gU2p3c0ClZqMD0hjyLMc3o5DMVsRfipER4MJkCLung1EPbDHdvZcQAv5dlWTaBLTXKkWB16oJpp0YxaWh502I5qaYpKI6UYt0liyhyiMF2-zkLplcCXvvkc0kTfQDAjqKWBR2uKMkd9GHFcJTOLIXat_xOQ8bxK2YF8iy2rpp-jEPLgirYyywPA-mDbJfky2KciOXEfBKMoJqDlD7B2gQLyMUNWEJtgoQ9T-kO5UIBqXGy4LV-myQZ_VtZJ05gAoTneb2Gc9EXwi_Qe4XElv_JU67i-6AaBB_TZbrB0wd9PU7yezM1kNHG4L4q_vw35_1lGyjwgjeDcbDR-Q6M1ksCEEY2yGby_NcP0ZsuYyelIsWyMer1hM_AQENi-k
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cardiovascular+outcomes+in+adults+with+hypertension+with+evening+versus+morning+dosing+of+usual+antihypertensives+in+the+UK+%28TIME+study%29%3A+a+prospective%2C+randomised%2C+open-label%2C+blinded-endpoint+clinical+trial&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Mackenzie%2C+Isla+S&rft.au=Rogers%2C+Amy&rft.au=Poulter%2C+Neil+R&rft.au=Williams%2C+Bryan&rft.date=2022-10-22&rft.issn=1474-547X&rft.eissn=1474-547X&rft.volume=400&rft.issue=10361&rft.spage=1417&rft_id=info:doi/10.1016%2FS0140-6736%2822%2901786-X&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0140-6736&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0140-6736&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0140-6736&client=summon